On Monday, BioXcel Therapeutics Inc (NASDAQ: BTAI) opened higher 16.85% from the last session, before settling in for the closing price of $0.41. Price fluctuations for BTAI have ranged from $0.36 to $4.17 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 53.60% annually for the last half of the decade. Company’s average yearly earnings per share was noted 72.25% at the time writing. With a float of $38.51 million, this company’s outstanding shares have now reached $42.46 million.
In an organization with 74 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 4.13%, operating margin of -3295.61%, and the pretax margin is -3119.33%.
BioXcel Therapeutics Inc (BTAI) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of BioXcel Therapeutics Inc is 20.36%, while institutional ownership is 6.57%. The most recent insider transaction that took place on Oct 03 ’24, was worth 3,450. In this transaction Chief Commercial Officer of this company sold 6,272 shares at a rate of $0.55, taking the stock ownership to the 19,011 shares. Before that another transaction happened on Oct 03 ’24, when Company’s insider sold 6,863 for $0.55, making the entire transaction worth $3,775. This insider now owns 23,770 shares in total.
BioXcel Therapeutics Inc (BTAI) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 72.25% per share during the next fiscal year.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
Check out the current performance indicators for BioXcel Therapeutics Inc (BTAI). In the past quarter, the stock posted a quick ratio of 1.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.15, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.56 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
Let’s dig in a bit further. During the last 5-days, its volume was 1.24 million. That was better than the volume of 0.84 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 36.70%. Additionally, its Average True Range was 0.06.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 13.70%, which indicates a significant decrease from 47.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 109.90% in the past 14 days, which was higher than the 96.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5665, while its 200-day Moving Average is $1.4199. However, in the short run, BioXcel Therapeutics Inc’s stock first resistance to watch stands at $0.5424. Second resistance stands at $0.6084. The third major resistance level sits at $0.6601. If the price goes on to break the first support level at $0.4247, it is likely to go to the next support level at $0.3730. Assuming the price breaks the second support level, the third support level stands at $0.3070.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
There are currently 42,748K shares outstanding in the company with a market cap of 23.04 million. Presently, the company’s annual sales total 1,380 K according to its annual income of -179,050 K. Last quarter, the company’s sales amounted to 210 K and its income totaled -13,650 K.
